BerGenBio delivered solid clinical efficacy data in 2019, and 2020 will be the year to harvest the results and initiate pivotal studies in AML and NSCLC. In addition, the proprietary Axl companion diagnostic and the Axl-antibody, tilvestamab, will also take important steps this year. We reiterate BUY at NOK 65. The next triggers will be clinical read-out at ASCO in June, communication regarding the FDA/EMA feedback and the study design of the next studies.
